Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.

Serpell M, Tripathi S, Scherzinger S, Rojas-Farreras S, Oksche A, Wilson M.

Patient. 2016 Feb;9(1):35-46. doi: 10.1007/s40271-015-0151-y.

2.

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group.

Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19.

PMID:
26494524
3.

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R; RELOXYN Study Group.

Lancet Neurol. 2013 Dec;12(12):1141-50. doi: 10.1016/S1474-4422(13)70239-4. Epub 2013 Oct 18. Erratum in: Lancet Neurol. 2013 Dec;12(12):1133.

PMID:
24140442
4.

Live cell imaging of G protein-coupled receptors.

Teichmann A, Schmidt A, Wiesner B, Oksche A, Schülein R.

Methods Mol Biol. 2012;897:139-69. doi: 10.1007/978-1-61779-909-9_7.

PMID:
22674164
5.

A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pain modulation: a human experimental study.

Arendt-Nielsen L, Andresen T, Malver LP, Oksche A, Mansikka H, Drewes AM.

Clin J Pain. 2012 Sep;28(7):623-7. doi: 10.1097/AJP.0b013e31823e15cb.

PMID:
22156892
6.

Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain.

Andresen T, Staahl C, Oksche A, Mansikka H, Arendt-Nielsen L, Drewes AM.

Br J Pharmacol. 2011 Oct;164(3):934-45. doi: 10.1111/j.1476-5381.2010.01180.x.

7.

Localisation of endothelin B receptor variants to plasma membrane microdomains and its effects on downstream signalling.

Grossmann S, Higashiyama S, Oksche A, Schaefer M, Tannert A.

Mol Membr Biol. 2009 Aug;26(5):279-92. doi: 10.1080/09687680903191682.

PMID:
19757321
8.

Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB.

Lättig J, Oksche A, Beyermann M, Rosenthal W, Krause G.

J Pept Sci. 2009 Jul;15(7):479-91. doi: 10.1002/psc.1146.

PMID:
19466696
9.

Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C.

Plant TD, Zöllner C, Kepura F, Mousa SS, Eichhorst J, Schaefer M, Furkert J, Stein C, Oksche A.

Mol Pain. 2007 Nov 14;3:35.

10.

Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo.

Niendorf S, Oksche A, Kisser A, Löhler J, Prinz M, Schorle H, Feller S, Lewitzky M, Horak I, Knobeloch KP.

Mol Cell Biol. 2007 Jul;27(13):5029-39. Epub 2007 Apr 23.

11.

Functional expression of mammalian receptors and membrane channels in different cells.

Eifler N, Duckely M, Sumanovski LT, Egan TM, Oksche A, Konopka JB, Lüthi A, Engel A, Werten PJ.

J Struct Biol. 2007 Aug;159(2):179-93. Epub 2007 Feb 3.

PMID:
17368047
12.

Mass-spectrometric identification of a novel angiotensin peptide in human plasma.

Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schlüter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J.

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):297-302. Epub 2006 Nov 30.

PMID:
17138938
13.

Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain.

Endres-Becker J, Heppenstall PA, Mousa SA, Labuz D, Oksche A, Schäfer M, Stein C, Zöllner C.

Mol Pharmacol. 2007 Jan;71(1):12-8. Epub 2006 Sep 27.

PMID:
17005903
14.

Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor.

Plant TD, Zöllner C, Mousa SA, Oksche A.

Exp Biol Med (Maywood). 2006 Jun;231(6):1161-4.

PMID:
16741069
15.

Endothelin A and endothelin B receptors differ in their ability to stimulate ERK1/2 activation.

Grantcharova E, Reusch HP, Beyermann M, Rosenthal W, Oksche A.

Exp Biol Med (Maywood). 2006 Jun;231(6):757-60.

PMID:
16740994
16.

N-terminal proteolysis of the endothelin B receptor abolishes its ability to induce EGF receptor transactivation and contractile protein expression in vascular smooth muscle cells.

Grantcharova E, Reusch HP, Grossmann S, Eichhorst J, Krell HW, Beyermann M, Rosenthal W, Oksche A.

Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1288-96. Epub 2006 Apr 6.

PMID:
16601236
17.

Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells.

Infanger M, Kossmehl P, Shakibaei M, Bauer J, Kossmehl-Zorn S, Cogoli A, Curcio F, Oksche A, Wehland M, Kreutz R, Paul M, Grimm D.

Cell Tissue Res. 2006 May;324(2):267-77. Epub 2006 Jan 24.

PMID:
16432709
18.

The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding.

Thielen A, Oueslati M, Hermosilla R, Krause G, Oksche A, Rosenthal W, Schülein R.

FEBS Lett. 2005 Sep 26;579(23):5227-35.

19.

Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction.

Giebing G, Tölle M, Jürgensen J, Eichhorst J, Furkert J, Beyermann M, Neuschäfer-Rube F, Rosenthal W, Zidek W, van der Giet M, Oksche A.

Circ Res. 2005 Sep 30;97(7):707-15. Epub 2005 Sep 1.

PMID:
16141412
20.

Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus.

de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM.

J Am Soc Nephrol. 2005 Oct;16(10):2872-80. Epub 2005 Aug 24.

21.

Live cell imaging of G protein-coupled receptors.

Wiesner B, Beyermann M, Oksche A.

Methods Mol Biol. 2005;306:173-202. No abstract available.

PMID:
15867469
22.

Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers.

Gregan B, Schaefer M, Rosenthal W, Oksche A.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S30-3.

PMID:
15838305
23.

Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway.

Hermosilla R, Oueslati M, Donalies U, Schönenberger E, Krause E, Oksche A, Rosenthal W, Schülein R.

Traffic. 2004 Dec;5(12):993-1005.

24.

Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.

Wüller S, Wiesner B, Löffler A, Furkert J, Krause G, Hermosilla R, Schaefer M, Schülein R, Rosenthal W, Oksche A.

J Biol Chem. 2004 Nov 5;279(45):47254-63. Epub 2004 Aug 19.

25.

Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers.

Gregan B, Jürgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A.

J Biol Chem. 2004 Jun 25;279(26):27679-87. Epub 2004 Apr 9.

26.

The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho.

Tamma G, Wiesner B, Furkert J, Hahm D, Oksche A, Schaefer M, Valenti G, Rosenthal W, Klussmann E.

J Cell Sci. 2003 Aug 15;116(Pt 16):3285-94. Epub 2003 Jun 26.

27.

The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process.

Grantcharova E, Furkert J, Reusch HP, Krell HW, Papsdorf G, Beyermann M, Schulein R, Rosenthal W, Oksche A.

J Biol Chem. 2002 Nov 15;277(46):43933-41. Epub 2002 Sep 10.

28.

Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus.

Marr N, Bichet DG, Hoefs S, Savelkoul PJ, Konings IB, De Mattia F, Graat MP, Arthus MF, Lonergan M, Fujiwara TM, Knoers NV, Landau D, Balfe WJ, Oksche A, Rosenthal W, Müller D, Van Os CH, Deen PM.

J Am Soc Nephrol. 2002 Sep;13(9):2267-77.

29.

Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides.

Oehlke J, Birth P, Klauschenz E, Wiesner B, Beyermann M, Oksche A, Bienert M.

Eur J Biochem. 2002 Aug;269(16):4025-32.

30.

Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus.

Marr N, Bichet DG, Lonergan M, Arthus MF, Jeck N, Seyberth HW, Rosenthal W, van Os CH, Oksche A, Deen PM.

Hum Mol Genet. 2002 Apr 1;11(7):779-89.

PMID:
11929850
31.

Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity.

Oksche A, Leder G, Valet S, Platzer M, Hasse K, Geist S, Krause G, Rosenthal A, Rosenthal W.

Mol Endocrinol. 2002 Apr;16(4):799-813.

PMID:
11923476
32.

The signal peptide of the G protein-coupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the endoplasmic reticulum membrane.

Köchl R, Alken M, Rutz C, Krause G, Oksche A, Rosenthal W, Schülein R.

J Biol Chem. 2002 May 3;277(18):16131-8. Epub 2002 Feb 19.

33.

The dispersed cell culture as model for functional studies of the subcommissural organ: preparation and characterization of the culture system.

Schöniger S, Wehming S, Gonzalez C, Schöbitz K, Rodríguez E, Oksche A, Yulis CR, Nürnberger F.

J Neurosci Methods. 2001 May 30;107(1-2):47-61.

PMID:
11389941
34.

Human subcommissural organ, with particular emphasis on its secretory activity during the fetal life.

Rodríguez EM, Oksche A, Montecinos H.

Microsc Res Tech. 2001 Mar 1;52(5):573-90. Review.

PMID:
11241867
35.

Evidence for downregulation of the endothelin-B-receptor by the use of fluorescent endothelin-1 and a fusion protein consisting of the endothelin-B-receptor and the green fluorescent protein.

Oksche A, Boese G, Horstmeyer A, Papsdorf G, Furkert J, Beyermann M, Bienert M, Rosenthal W.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S44-7.

PMID:
11078332
36.

Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM.

J Clin Invest. 2000 Jul;106(1):107-16.

37.

Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor.

Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, Rosenthal W.

Mol Pharmacol. 2000 Jun;57(6):1104-13.

PMID:
10825380
38.
39.

The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues.

Schülein R, Zühlke K, Oksche A, Hermosilla R, Furkert J, Rosenthal W.

FEBS Lett. 2000 Jan 21;466(1):101-6. Erratum in: FEBS Lett 2000 May 4;473(1):124.

40.

Molecular and conformational features of a transport-relevant domain in the C-terminal tail of the vasopressin V(2) receptor.

Krause G, Hermosilla R, Oksche A, Rutz C, Rosenthal W, Schülein R.

Mol Pharmacol. 2000 Feb;57(2):232-42.

PMID:
10648632
41.

Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells.

Andersen-Beckh B, Dehe M, Schülein R, Wiesner B, Rutz C, Liebenhoff U, Rosenthal W, Oksche A.

Kidney Int. 1999 Aug;56(2):517-27.

42.

Polarized cell surface expression of the green fluorescent protein-tagged vasopressin V2 receptor in Madin Darby canine kidney cells.

Schülein R, Lorenz D, Oksche A, Wiesner B, Hermosilla R, Ebert J, Rosenthal W.

FEBS Lett. 1998 Dec 18;441(2):170-6.

43.

Aquaporin-2 expression in primary cultured rat inner medullary collecting duct cells.

Maric K, Oksche A, Rosenthal W.

Am J Physiol. 1998 Nov;275(5):F796-801. doi: 10.1152/ajprenal.1998.275.5.F796.

PMID:
9815137
44.
45.

The molecular basis of nephrogenic diabetes insipidus.

Oksche A, Rosenthal W.

J Mol Med (Berl). 1998 Apr;76(5):326-37. Review.

PMID:
9587067
46.

Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C-terminus.

Oksche A, Dehe M, Schülein R, Wiesner B, Rosenthal W.

FEBS Lett. 1998 Mar 6;424(1-2):57-62.

47.

Congenital nephrogenic diabetes insipidus.

Bichet DG, Oksche A, Rosenthal W.

J Am Soc Nephrol. 1997 Dec;8(12):1951-8. Review. No abstract available.

48.

Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus.

Oksche A, Möller A, Dickson J, Rosendahl W, Rascher W, Bichet DG, Rosenthal W.

Hum Genet. 1996 Nov;98(5):587-9.

PMID:
8882880
49.

Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.

Oksche A, Schülein R, Rutz C, Liebenhoff U, Dickson J, Müller H, Birnbaumer M, Rosenthal W.

Mol Pharmacol. 1996 Oct;50(4):820-8.

PMID:
8863826
50.

[In memoriam Berta Scharrer (1906-1995)].

Oksche A.

Ann Anat. 1996 Aug;178(4):293-8. German. No abstract available.

PMID:
8928935

Supplemental Content

Loading ...
Support Center